By Ethan Covey
Cabotegravir, an investigational novel integrase inhibitor (INI), does not appear to cause weight gain, according to a phase 2 trial presented at CROI 2019, in Seattle (abstract 34).
Data from the study, which looked at safety issues in HIV-negative people, were presented by Raphael J. Landovitz, MD, an associate professor of medicine at the UCLA CARE Center (Center for Clinical AIDS Research and Education), in Los Angeles.
INIs, which are a common component of antiretroviral